Mark Lowenthal joined NIST in 2007 following a post-doctoral position at the University of Colorado Health Sciences Center and a research fellowship at the National Cancer Institute (NCI/NIH). Mark received a Ph.D. from the University of Maryland in analytical chemistry.
His research activities at NIST focus on development and analysis of reference standards that support measurements of clincal proteins and therapeutic oligonucleotides, sugars and metabolites, including NIST's first mRNA drug-like substance reference material (RGTM 10202 FLuc mRNA) and first glycan-based Standard Reference Material (SRM 3655), as well as standards to support measurements of cardiac troponin I, bovine serum albumin, immune-modulating impurities, amino acids, and more.
Mark has co-authored over 50 peer-reviewed publications and book chapters. He is leader of the JCTLM protein team, and a member of the IFCC working group on troponin I, the CCQM PAWG, ASTM nano enabled medicines, and NIIMBL Vaccine Manufacturing Steering committee.